Astex and Genentech Partner to Advance Breast Cancer Drugs
CAMBRIDGE, United Kingdom, July 6, 2026 Astex Pharmaceuticals has entered into an exclusive worldwide research collaboration and license agreement...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
CAMBRIDGE, United Kingdom, July 6, 2026 Astex Pharmaceuticals has entered into an exclusive worldwide research collaboration and license agreement...
TAMPA, Fla., June 15, 2026 TuHURA Biosciences, Inc. has announced the filing of an Investigational New Drug (IND) application...
WARSAW, Poland, June 3, 2026 Ingenix, an emerging artificial intelligence company focused on transforming drug discovery through advanced biological...
NEWTON, Mass., June 1, 2026 Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading...
COLUMBUS, Ohio and CHICAGO, June 1, 2026 Paradigm Health has announced the successful implementation of its SPIRE (Scalable Platform...
IRVINE, California, May 29, 2026 PeproMene Bio, Inc. has announced that updated clinical data from its ongoing Phase 1...
AUSTIN, Texas | May 2026 Natera, Inc. announced a new collaboration with Diakonos Oncology Corp. to utilize its personalized...
CHENGDU, China, May 29, 2026 Kelun-Biotech has presented pivotal Phase II clinical trial results for its next-generation selective RET...
CHICAGO, Ill., May 29, 2026 Johnson & Johnson has announced encouraging long-term results from the Phase 1/1b CHRYSALIS-2 study,...
RALEIGH, N.C. | May 28, 2026 Parexel announced that two oncology-focused research posters have been accepted for presentation at...
